HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues

肝细胞癌 乙型肝炎表面抗原 医学 内科学 乙型肝炎病毒 胃肠病学 肿瘤科 病毒学 癌症研究 病毒
作者
Terry Cheuk‐Fung Yip,Grace Lai‐Hung Wong,Henry Lik‐Yuen Chan,Yee‐Kit Tse,Kelvin Long‐Yan Lam,Grace Lui,Vincent Wai‐Sun Wong
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:70 (3): 361-370 被引量:242
标识
DOI:10.1016/j.jhep.2018.10.014
摘要

•Patients without complete viral suppression have the highest risk of HCC.•NA-induced HBsAg seroclearance leads to lower HCC risk than complete viral suppression alone.•Patients with HBsAg seroclearance and complete viral suppression have a similar risk of hepatic events. Background & AimsIn treated patients with chronic hepatitis B (CHB) who have achieved complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of hepatocellular carcinoma (HCC) and hepatic events in nucleos(t)ide analogue (NA)-treated patients with and without HBsAg seroclearance.MethodsWe performed a territory-wide retrospective cohort study on all patients with CHB who had received entecavir and/or tenofovir disoproxil fumarate (TDF) for at least 6 months between 2005 and 2016 from Hospital Authority, Hong Kong. Patients’ demographics, comorbidities, and laboratory parameters were analyzed. The primary outcome was HCC. The secondary outcomes were hepatic events including cirrhotic complications, liver transplantation, and liver-related mortality.ResultsA total of 20,263 entecavir/TDF-treated patients with CHB were identified; 17,499 (86.4%) patients had complete viral suppression; 376 (2.1%) achieved HBsAg seroclearance. At a median (interquartile range) follow-up of 4.8 (2.8–7.0) years, 603 (3.5%) and 121 (4.4%) patients with and without complete viral suppression developed HCC; 2 (0.5%) patients with HBsAg seroclearance developed HCC. Compared to complete viral suppression, lack of complete viral suppression was associated with a higher risk of HCC (7.8% vs. 5.6% at 8 years, Gray’s test, p <0.001) (adjusted hazard ratio [aHR] 1.69; 95% CI 1.36–2.09; p <0.001); patients who achieved functional cure had a lower risk of HCC (0.6% vs. 5.6% at 8 years, Gray’s test, p <0.001) (aHR 0.24; 95% CI 0.06–0.97; p = 0.045) but not hepatic events (aHR 0.99; 95% CI 0.30–3.26; p = 0.991).ConclusionsPatients who achieved HBsAg seroclearance on top of complete viral suppression with entecavir/TDF treatment may have a lower risk of HCC but not hepatic events.Lay summaryWe investigated 20,263 nucleos(t)ide analogue (NA)-treated patients with chronic hepatitis B. Patients with NA-induced hepatitis B surface antigen seroclearance on top of complete viral suppression have a lower risk of hepatocellular carcinoma but not hepatic events than those only achieving complete viral suppression under prolonged NA treatment. In treated patients with chronic hepatitis B (CHB) who have achieved complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of hepatocellular carcinoma (HCC) and hepatic events in nucleos(t)ide analogue (NA)-treated patients with and without HBsAg seroclearance. We performed a territory-wide retrospective cohort study on all patients with CHB who had received entecavir and/or tenofovir disoproxil fumarate (TDF) for at least 6 months between 2005 and 2016 from Hospital Authority, Hong Kong. Patients’ demographics, comorbidities, and laboratory parameters were analyzed. The primary outcome was HCC. The secondary outcomes were hepatic events including cirrhotic complications, liver transplantation, and liver-related mortality. A total of 20,263 entecavir/TDF-treated patients with CHB were identified; 17,499 (86.4%) patients had complete viral suppression; 376 (2.1%) achieved HBsAg seroclearance. At a median (interquartile range) follow-up of 4.8 (2.8–7.0) years, 603 (3.5%) and 121 (4.4%) patients with and without complete viral suppression developed HCC; 2 (0.5%) patients with HBsAg seroclearance developed HCC. Compared to complete viral suppression, lack of complete viral suppression was associated with a higher risk of HCC (7.8% vs. 5.6% at 8 years, Gray’s test, p <0.001) (adjusted hazard ratio [aHR] 1.69; 95% CI 1.36–2.09; p <0.001); patients who achieved functional cure had a lower risk of HCC (0.6% vs. 5.6% at 8 years, Gray’s test, p <0.001) (aHR 0.24; 95% CI 0.06–0.97; p = 0.045) but not hepatic events (aHR 0.99; 95% CI 0.30–3.26; p = 0.991). Patients who achieved HBsAg seroclearance on top of complete viral suppression with entecavir/TDF treatment may have a lower risk of HCC but not hepatic events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
zaza发布了新的文献求助10
2秒前
龙傲天完成签到,获得积分20
2秒前
2秒前
田様应助阳大哥采纳,获得10
3秒前
JRZ完成签到,获得积分10
3秒前
爪人猫完成签到,获得积分10
4秒前
5秒前
5秒前
可爱的函函应助深情海秋采纳,获得10
6秒前
搬砖打工人完成签到,获得积分10
6秒前
6秒前
香蕉静芙发布了新的文献求助10
6秒前
苏雅霏发布了新的文献求助10
6秒前
我是老大应助一一采纳,获得10
7秒前
豆子发布了新的文献求助10
8秒前
msk完成签到 ,获得积分20
8秒前
liun发布了新的文献求助10
9秒前
小二郎应助情殇采纳,获得10
9秒前
10秒前
11秒前
我是老大应助zaza采纳,获得50
11秒前
wst完成签到,获得积分10
11秒前
顺利静竹完成签到,获得积分20
12秒前
12秒前
hrioc完成签到,获得积分10
12秒前
奋斗向南发布了新的文献求助10
13秒前
Orange应助爱撒娇的惋清采纳,获得10
14秒前
15秒前
坦率的大神完成签到 ,获得积分10
15秒前
wst发布了新的文献求助10
16秒前
湫白白发布了新的文献求助10
16秒前
HL完成签到,获得积分10
16秒前
17秒前
tyx给tyx的求助进行了留言
17秒前
18秒前
18秒前
奋斗瑶发布了新的文献求助10
18秒前
科研小助发布了新的文献求助10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971277
求助须知:如何正确求助?哪些是违规求助? 3516009
关于积分的说明 11180382
捐赠科研通 3251075
什么是DOI,文献DOI怎么找? 1795664
邀请新用户注册赠送积分活动 875988
科研通“疑难数据库(出版商)”最低求助积分说明 805209